SCHEMBL701483

SCHEMBL701483

O=C(CCCC1CCCCN1S(=O)(=O)c1ccccc1C(F)(F)F)N1CCC(CCCN2CCCC2)(c2ccncc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 9/20 0.40
KMT2A Q03164 1/20 0.38
HTR1A P08908 4/20 0.36
HTR1D P28221 3/20 0.36
HTR2B P41595 3/20 0.36
DRD2 P14416 3/20 0.36
DRD3 P35462 2/20 0.36
HCRTR1 O43613 1/20 0.36
CCR1 P32246 1/20 0.34
KCNQ1 P51787 1/20 0.34
SFRP1 Q8N474 1/20 0.34
GFER P55789 1/20 0.34
HTR2A P28223 2/20 0.33
HTR1B P28222 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1B P35368 1/20 0.33
TACR1 P25103 1/20 0.33
HTR6 P50406 1/20 0.33
CCR5 P51681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701104 0.92 HTR7 (0.39) HTR7HTR1AHTR1DHTR2BDRD2
SCHEMBL702140 0.89 KMT2A (0.37) HTR7KMT2AHTR1AHCRTR1CCR1
SCHEMBL700842 0.88 HTR7 (0.51) HTR7HTR1AHTR1DHTR2BDRD2
SCHEMBL3442292 0.81 HTR7 (0.36) HTR7HTR1AHTR1DHTR2BDRD2
SCHEMBL703365 0.81 TACR1 (0.36) HTR7KMT2AHCRTR1CCR1KCNQ1
SCHEMBL701153 0.81 CCR1 (0.36) HTR7HTR1AHTR1DHTR2BDRD2
SCHEMBL699942 0.80 HTR7 (0.36) HTR7HTR1A
SCHEMBL4296232 0.78 HTR7 (0.38) HTR7HTR1AHTR1DHTR2BDRD2
SCHEMBL700983 0.76 LMNA (0.34) KMT2ACCR1GFERTACR1CCR5
SCHEMBL3441500 0.75 HTR7 (0.49) HTR7HTR1AHTR1DHTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124624-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-02-28 US claimed
EP-2262791-A2 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-12-22 EP claimed
US-20090264407-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US claimed
WO-2009124734-A2 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-10-15 WO claimed
US-8124624-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-02-28 US disclosed
US-20090264407-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264407-A1 Substituted Sulfonamide Compounds CNR1, SUCNR1, OPRL1 HTR7 522/4885KMT2A 3631/4885HTR1A 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.